Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-05-20 |
Ablynx (Belgium) |
€ 100 million |
private placement |
|
Cancer - Oncology - Immunological diseases - Respiratory diseases |
Private placement |
2015-05-20 |
Companion Medical (USA - CA) |
|
series B financing round |
Eli Lilly (USA - IN) Diamyd Medical (Sweden) |
Metabolic diseases |
Series B financing round |
2015-05-20 |
RegenXBio (USA - MD) |
$70.5 million |
series D financing round |
Venrock (USA - CA) Brookside Capital (USA - MA) Vivo Capital (USA - CA) Deerfield Management (USA - NY) Fidelity BioSciences (USA - MA) a fund managed by Janus Capital Management (USA - CO); Jennison Associates (USA - NY) on behalf of clients; Perceptive Advisors (USA - NY) QVT Financial (USA - NY) Tourbillon Global Ventures; Sectoral Asset Management (Canada) Cormorant Asset Management (USA - MA) Foresite Capital Management (USA - CA) RTW Investments (USA - NY) and two undisclosed blue-chip investment funds |
Rare diseases - Genetic diseases |
Series D financing round |
2015-05-20 |
Auris Medical (Switzerland) |
$22.9 million |
private placement |
|
Otorhinolaryngology |
Private placement |
2015-05-19 |
Galapagos (Belgium) |
€ 279 million |
IPO |
|
|
IPO |
2015-05-19 |
Anagenesis Biotechnologies (France) |
undisclosed |
financing round |
Cap Innov’Est (France) |
Neuromuscular diseases - Regenerative medicine |
Financing round |
2015-05-18 |
Abcodia (UK) |
£5.25 million |
financing round |
Cambridge Innovation Capital (CIC) (UK) Scottish Equity Partners (SEP) (UK) Albion Ventures (UK) UCL Business (UK) |
Diagnostic - Cancer - Oncology |
Financing round |
2015-05-18 |
Oryzon Genomics (Spain) |
$270,000 |
grant |
The Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY) |
Neurodegenerative diseases |
Grant |
2015-05-15 |
Cortendo (Sweden) |
$33.2 million |
private placement |
TVM Capital (Germany) Longwood Capital (USA - China) Granite Point Capital (USA - MA) RA Capital (USA - MA) New Enterprise Associates (USA - MD) Broadfin Capital (USA - NY) HealthCap (Sweden) |
Rare diseases - Hormonal diseases - Endocrine diseases |
Private placement |
2015-05-15 |
Circassia Pharmaceuticals (UK) |
£275 million (€ 380 million) |
private placement |
|
Allergic diseases - Inflammatory diseases - Respiratory diseases |
Private placement |
2015-05-14 |
Denali Therapeutics (USA - CA) |
$ 217 million |
financing round |
Fidelity Biosciences (USA - MA), ARCH Venture Partners (USA - IL), Flagship Ventures (USA - MA), Alaska Permanent Fund (USA - AK), sovereign wealth funds, public mutual funds and private family offices |
Neurodegenerative diseases |
Financing round |
2015-05-13 |
Cell Cure Neurosciences (Israel) |
6.24 million shekels (approximately $1.61 million ) |
grant |
Office of the Chief Scientist (OCS -Israel) |
|
Grant |
2015-05-12 |
Juventas Therapeutics (USA - OH) |
$13.5 million |
|
Green Cross Holdings (South Korea) POSCO Capital (South Korea) other new and existing investors |
Cardiovascular diseases |
Series B financing round |
2015-05-12 |
Ixico (UK) |
£1 million |
grant |
Innovate UK (UK) |
CNS diseases |
Grant |
2015-05-12 |
Affimed (Germany) |
$37.1 million |
private placement |
|
Cancer - Oncology |
Private placement |
2015-05-12 |
Antabio (France) |
€4 million |
grant |
Wellcome Trust (UK) |
Infectious diseases - Rare diseases |
Grant |
2015-05-12 |
Bavarian Nordic (Denmark) |
€ 50 million |
loan |
European Investment Bank (EIB) (EU) |
Infectious diseases |
Loan |
2015-05-11 |
Adaptimmune (UK) |
$175.7 million |
IPO |
|
Cancer - Oncology |
IPO |
2015-05-08 |
Neurovive Pharmaceutical (Sweden) |
SEK 70 million (€ 7.5 million) |
private placement |
|
|
Capital increase |
2015-05-06 |
Atyr Pharma (USA - CA) |
|
IPO |
|
Cancer - Oncology - Rare diseases - Genetic diseases |
IPO |